Meta reached an $18 billion settlement with 48 states over social media’s harm to children. Abercrombie posted another strong quarter, while inflation remained elevated and several small-cap names saw huge moves. 

Today’s edition breaks down the biggest market stories and the stocks moving the most.

The European Central Bank just confirmed it.

Gold: 27% of global reserves. U.S. Treasuries: 22%.

A year ago, those numbers were reversed.

The institutions that print money are quietly trading dollars for gold — at the fastest pace in 50 years. JP Morgan forecasts $8,000 ahead.

Don't be the last one to know.

Click here to get the free Wealth Preservation Guide — see the 3 steps to follow the central bank trade.

You’re looking at two technology suppliers benefiting from powerful defense and AI spending trends. Elite Trade Club Insider readers are seeing what the headline numbers miss: one CEO’s eight-figure sale was specifically designed to pay for a stock-option exercise, while a director voluntarily bought more than $500,000 after his stock dropped sharply in a matter of days.

Every day, insiders and institutions move millions before the market catches on. We surface the data behind those moves before the rest of the market sees it.

A subscription gets you:

$25/mo or $250/yr. 30-day money back guarantee. Cancel anytime. Founding member pricing: lock in $25/mo before we raise it.

Nvidia has beaten estimates in each of the past 14 quarters and is navigating a hardware transition from Blackwell to its next-generation Rubin architecture — what veterans call a “handoff quarter” where expectations historically get tested; options markets priced in a 5.4% post-earnings swing, and CEO Jensen Huang speaks at 5pm ET.

Meta settled with 48 state attorneys general for $18 billion, ending a trial built on internal documents showing executives were aware that its products harmed minors; the stock rose 1.4% as investors treated a settled liability as better than three more years of litigation.

The Fed’s preferred inflation gauge held at 3.7% in July — unchanged from June and well above the 2% target — giving Kevin Warsh little comfort ahead of his Jackson Hole speech Friday.

Boston Scientific fell 4.5% after a cyberattack disrupted its ability to process and ship cardiac device orders, with no timeline for full restoration.

Abercrombie & Fitch reported record Q2 net sales for its 15th consecutive quarter of growth, with adjusted EPS of $4.17 crushing an estimate of roughly $1.99, including about $100 million in tariff refunds; the company raised its full-year guidance.

Waystar launched four new AI-powered capabilities designed to automate healthcare revenue-cycle work, including rejected-claim resubmissions, conversational analytics, clinical-documentation reviews and patient financial engagement across a network processing more than $2.4 trillion in gross claims annually.

Early users cut data-analysis time by as much as 75%. Waystar expects its clinical-documentation tool to reduce review time by roughly 25% as the company expands automation across healthcare payment workflows.

Keysight Technologies’ EDA software helped AttoTude cut chip-design cycles by more than 50% to under six weeks while achieving first-pass silicon success across advanced RF, sub-THz and THz designs aimed at AI and data-center applications.

AttoTude expanded its use of Keysight’s Advanced Design System across the full integrated-circuit workflow, giving engineers shared design management and simulation tools as its interconnect technology targets data rates reaching 800G per lane.

Kohl’s raised its full-year earnings outlook after second-quarter adjusted EPS reached $1.28, helped by roughly $150 million in tariff refunds. The retailer also announced plans to restart share repurchases with up to $100 million of stock purchases this year.

Comparable sales still declined 0.9%, but gross margin expanded 305 basis points and long-term debt fell to its lowest level since 2007, giving Kohl’s more financial flexibility while it works through continued pressure on lower- and middle-income shoppers.

Bath & Body Works raised its full-year adjusted EPS guidance to $2.60 to $2.80 after second-quarter earnings beat expectations, with approximately $80 million in tariff refunds helping adjusted EPS reach $0.62 while gross margin expanded 440 basis points.

Sales still declined 2.3% to $1.5 billion, but digital revenue returned to growth and international sales accelerated as the retailer expands through channels including Amazon and Ulta while targeting roughly $200 million of cost savings this year.

Parsons Corporation secured a position on a $14 billion missile intelligence contract supporting the U.S. Missile & Space Intelligence Center, opening the door to task orders across scientific intelligence, systems integration and analytical support.

The multiple-award COMET program gives Parsons another large federal contract vehicle, with future work spanning research, development and sustainment of hardware and software used to evaluate missile and space threats across the Defense Intelligence Enterprise.

AeroVironment received a $51 million U.S. Army order for additional Switchblade 600 loitering munitions, including Block 2 systems and Block 1 units tied to a Foreign Military Sale for a U.S. ally.

The award sits under the Army’s five-year, $990 million Lethal Unmanned Systems contract and extends follow-on procurement of the long-range precision weapon, adding another production order to AeroVironment’s defense backlog amid sustained demand for loitering munitions.

The headlines keep getting bigger.

New IPOs, soaring valuations, and speculative bets are dominating the market conversation.

But one longtime Wall Street veteran believes investors may be overlooking growing risks beneath the surface.

In a new free briefing, he explains what concerns him most and the steps he's taking to prepare.

Watch the Free Analysis.

Dycom Industries beat second-quarter estimates and raised its full-year outlook, reporting adjusted EPS of $5.29 on $2.0 billion in revenue as demand remained strong across fiber, wireless and building-systems projects despite a $150 million wireless revenue shift into fiscal 2028.

Communications margins remained under pressure, but Dycom’s broader infrastructure pipeline continues to benefit from network upgrades and data-center construction, giving the company additional growth channels beyond any single customer or project cycle.

Donaldson Company posted record fourth-quarter sales above $1 billion for the first time, with revenue rising 8% and adjusted EPS reaching $1.15 as stronger volume, pricing, and operational improvements lifted its filtration businesses.

Operating margin reached a company record of 17.5%, while management expects fiscal 2027 sales to grow 5.5% to 9.5% as industrial, mobile, and life-sciences demand supports another year of expansion.

Revolution Medicines won FDA approval for Rasonque, its once-daily targeted pill for previously treated metastatic pancreatic cancer, after a 500-patient study showed median overall survival of 13.2 months compared with 6.7 months for standard chemotherapy.

Rasonque is the first approved drug designed to block multiple forms of the RAS protein, giving Revolution Medicines a commercial foothold in one of oncology’s hardest-to-treat diseases after receiving an accelerated review through the FDA’s national priority voucher program.

Abbott received FDA approval for Libre Duo, the first U.S. wearable designed to continuously track both glucose and ketone levels in a single device, expanding its diabetes-monitoring franchise with a system cleared for patients aged two and older.

The 10-day sensor gives Abbott another differentiated product in continuous monitoring, combining two measurements that previously required separate testing while extending the Libre platform beyond glucose management into earlier detection of dangerous ketone buildup.

Cre8 Enterprise [CRE] $6.81 (+164.98%)

Cre8 Enterprise is a commercial services company that runs at a trailing P/E of 18x on positive EPS of $0.37 — meaning it’s actually profitable, which puts it in an unusual category for stocks that double in a single session.

The move came on 1,649x relative volume: a catalyst and institutional repositioning. At $5.18 million in total value, any concentrated buying creates an outsized print.

Expion360 [XPON] $9.17 (+74.00%)

Expion360 makes lithium iron phosphate batteries for recreational vehicles and marine vessels.

The company announced a transformative strategic partnership on Monday and has now run roughly 96% on Monday, fallen 15% on Tuesday, and surged 74% on Wednesday in a pattern driven by thin-float mechanics amplifying the genuine commercial news underneath.

The partnership is real; the day-to-day volatility is positioning.

Abercrombie & Fitch [ANF] $147.75 (+35.59%)

Abercrombie reported record Q2 net sales of $1.27 billion, its 15th consecutive quarter of growth, with adjusted EPS of $4.17 against analyst expectations of roughly $1.99.

The Abercrombie flagship brand delivered 8% net sales growth and 4% comparable sales improvement.

Management raised full-year guidance and cited a “strong start to August.” When a retailer beats by 110% on EPS and says August is going well, the stock doesn’t wait. Buy rated.

Greenland Mines [GRML] $5.04 (-48.09%)

Greenland Mines extracts rare earth minerals from Greenland’s substantial deposits — a company whose entire value proposition is geopolitical (Greenland’s rare earths as an alternative to Chinese supply chains).

The stock fell 48% on a development that called into question either the financing, the licensing timeline, or the strategic positioning of its flagship project. Strong Buy rating, which tells you analysts still believe in the long-term thesis even after a session like this.

Wetour Robotics [WETO] $17.28 (-38.96%)

Wetour Robotics makes intelligent transportation robots and completed a 1-for-100 reverse split in August to regain Nasdaq compliance.

The stock ran 33% on Monday, crashed Wednesday by 38% — this is what post-split thin-float volatility looks like when the float is this small and positioning is this directional.

The underlying business hasn’t changed across three sessions with triple-digit swings.

IP Strategy Holdings [IPST] $5.99 (-23.01%)

IP Strategy Holdings was up 107% on Friday and up another 22% on Monday. Today it gives back 23%. The pattern across three sessions is entirely mechanical.

A momentum run in a micro-cap name exhausts its buyers, the positioning reverses, and the stock gives back a portion of the gains without any change in fundamental outlook.

There is speculation that Trump could sign an order updating how America's gold reserves are valued, a figure that has not changed since 1973.

Past resets of this kind have historically led to strong moves in related assets.

See what the order could mean for your money.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.